Close this search box.

List of Publicly Traded Small-Cap Biotech Companies Listed on Major U.S. Exchanges

This list includes small-sized biotech companies with market capitalizations between 300 million and two billion dollars. We update this page at the start of every month so it is possible that a company’s market cap might fall below 300 million or go above two billion between updates. In parentheses you will find a short description or areas of focus for the company. Additional biotech companies can be found in the following sections:

List of Biotech Companies

Large-Cap Biotech Stocks

Mid-Cap Biotech Stocks

Micro-Cap Biotech Stocks

Nano-Cap Biotech Stocks

Molecular Diagnostics

In parentheses you will find a short description or areas of focus for the company. A comparison widget that shows trend, earnings per share (EPS), P/E ratio and beta for each of the companies on this list can be accessed through the link below.

Small-Cap Biotech Industry Comparison Widget

Select the company’s link to access charts, news links and company website and social media information.

Biotech: Small-Cap Stocks

Ablynx NV (ABLX) (IPO October 25, 2017; biopharmaceutical company: Nanobody platform: multiple therapeutic areas)

AC Immune SA (ACIU) (IPO September 23: biopharmaceutical company focused on diseases that are associated with protein misfolding)

Anika Therapeutics Inc. (ANIK) (Therapeutic products for tissue protection, healing and repair; animal health, ophthalmic, joint health and orthopedic products, surgical products to treat ENT disorders, wound care products)

Apellis Pharmaceuticals, Inc. (APLS) (IPO November 9, 2017; biopharmaceutical company: complement-dependent autoimmune and inflammatory diseases)

BioSpecifics Technologies Corp (BSTC) (Biopharmaceutical company: injectable collagenase used for treatment of Dupuytren’s contracture and Peyronie’s disease)

Cellect Biotechnology Ltd. (APOP) (IPO July 29, 2016: biotech company with functional stem cells selection platform)

Concert Pharmaceuticals, Inc. (CNCE) (CNS disorders, renal disease, inflammation and cancer)

Editas Medicine, Inc. (EDIT) (IPO February 3, 2016: Genome editing company)

Emergent Biosolutions, Inc. (EBS) (Biopharmaceutical company: therapeutics and vaccines in hematology/oncology; transplantation and infectious disease; biological defense products)

FibroGen, Inc. (FGEN) (Biopharmaceutical company: anemia in chronic kidney disease, liver fibrosis, pancreatic cancer, corneal blindness)

Five Prime Therapeutics, Inc. (FPRX) (Protein therapeutics)

InflaRx N.V. (IFRX) (IPO November 8, 2017; biopharmaceutical company: C5a inhibitors)

Inovio Pharmaceuticals, Inc. (INO) (Cancer, infectious diseases, vaccines)

La Jolla Pharmaceutical Company (LJPC) (Biopharmaceutical company: therapies for patients suffering from life-threatening diseases)

Progenics Pharmaceuticals Inc. (PGNX) (Oncology company: diagnostic and therapeutic needs of prostate cancer patients)

PTC Therapeutics, Inc. (PTCT) (Biopharmaceutical company: oral treatments)

Rhythm Pharmaceuticals, Inc. (RYTM) (IPO October 5, 2017; biopharmaceutical company: rare genetic deficiencies that lead to metabolic disorders)
Theravance Biopharma, Inc. (TBPH) (Biopharmaceutical company: diseases of the lung, gastrointestinal tract, infectious diseases)

Wave Life Sciences Ltd. (WVE) (IPO in November 2015: Biopharmaceutical company; stereopure nucleic acid therapeutic candidates)

Zai Lab Limited (ZLAB) (IPO September 20, 2017; biopharmaceutical company: autoimmune diseases, cancer, infectious diseases)


Revance Therapeutics, Inc. (RVNC) (Biopharmaceutical company: botulinum toxin products used in aesthetic and therapeutic applications)

Sienna Biopharmaceuticals, Inc. (SNNA) (IPO July 27, 2017; biopharmaceutical company: dermatology and aesthetics)


Aimmune Therapeutics, Inc. (AIMT) (IPO in August 2015: Biopharmaceutical company: allergies)

DBV Technologies S.A. (DBVT) (France: therapies for food and pediatric allergy patient)


Achaogen, Inc. (AKAO) (Biopharmaceutical company: antibacterials to treat multi-drug resistant gram-negative infections)


Immunomedics, Inc. (IMMU) (Biopharmaceutical company: antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases)

PDL BioPharma, Inc. (PDLI) (Patents and royalty assets: antibody humanization patents)

Prothena Corporation plc (PRTA) (Ireland: therapeutic monoclonal antibodies directed specifically to disease-causing proteins)

Xencor, Inc. (XNCR) (Antibody therapeutics: autoimmune disorders, asthma and allergic diseases, cancer)


Organovo Holdings, Inc. (ONVO) (3D bioprinting technology)


Coherus BioSciences, Inc. (CHRS) (Biosimilar pure play)


Cerus Corporation (CERS) (Biomedical products company: blood safety)

Global Blood Therapeutics Inc. (GBT) (Therapeutics for patients with grievous blood-based disorders)

Portola Pharmaceuticals, Inc. (PTLA) (Biopharmaceutical company: thrombosis and hematological diseases)


Clementia Pharmaceuticals Inc. (CMTA) (IPO August 2, 2017; biopharmaceutical company: bone and other diseases)


Adaptimmune Therapeutics plc (ADAP) (IPO in May 2015, United Kingdom, biopharmaceutical company: cancer immunotherapy products)

Aduro BioTech, Inc. (ADRO) (IPO in April 2015: Cancer immunotherapy; pancreatic cancer)

Advaxis, Inc. (ADXS) (Clinical-stage biotechnology company: immunotherapies to treat cancer)

Arcus Biosciences, Inc. (RCUS) (IPO March 15, 2018; biopharmaceutical company: cancer immunotherapies)

argenx SE (ARGX) (IPO May 18, 2017; biotech company: autoimmune diseases and cancer)

ARMO BioSciences, Inc. (ARMO)  (IPO January 26, 2018; immuno-oncology company)

Array BioPharma Inc. (ARRY) (Biopharmaceutical company: targeted small molecule drugs used to treat patients afflicted with cancer)

Atara Biotherapeutics, Inc. (ATRA) (Molecularly-targeted product candidates and T-cell product candidates; cancer, kidney disease and other illnesses)

Athenex, Inc. (ANTX) (IPO June 14, 2017; biopharmaceutical company: cancer)

Beigene, Ltd. (BGNE) (IPO February 3, 2016: Biopharmaceutical company with therapeutics designed to treat cancer)

Bellicum Pharmaceuticals, Inc. (BLCM) (Biopharmaceutical company: cellular immunotherapies for various forms of cancer; hematological and solid tumors, orphan inherited blood disorders)

BeyondSpring Inc. (BYSI) (IPO March 9, 2017; cancer therapies)

Blueprint Medicines Corporation (BPMC) (IPO in April 2015: Biopharmaceutical company: kinase inhibitors for genomically defined cancers)

Cellectis SA (CLLS) (IPO in March 2015, France: Gene-editing company; cancer therapies based on engineered T cells)

Celldex Therapeutics, Inc. (CLDX) (Therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines; brain cancer, triple negative breast cancer)

ChemoCentryx, Inc. (CCXI) (Biopharmaceutical company: orally-administered therapeutics for the treatment of autoimmune diseases, inflammatory disorders and cancer)

Corvus Pharmaceuticals, Inc. (CRVS) (IPO March 23, 2016: Biopharmaceutical company focused on immuno-oncology therapies for cancer)

Cue Biopharma, Inc. (CUE) (IPO January 2, 2018; biopharmaceutical company: cancer and autoimmune disorders)

Curis, Inc. (CRIS) (Drug candidates for the treatment of human cancers)

CytomX Therapeutics Inc. (CTMX) (IPO in October 2015: Biopharmaceutical company; antibody therapeutics, oncology)

Epizyme, Inc. (EPZM) (Biopharmaceutical company: therapeutics for patients with genetically defined cancers)

ERYTECH Pharma S.A. (ERYP) (IPO November 10, 2017; France: biopharmaceutical company: cancer)

G1 Therapeutics, Inc. (GTHX) (IPO May 17, 2017; biopharmaceutical company: cancer)

Geron Corporation (GERN) (Biopharmaceutical company: telomerase inhibitor in hematologic myeloid malignancies)

Halozyme Therapeutics, Inc. (HALO) (Oncology therapies that target the tumor microenvironment)

Iovance Biotherapeutics, Inc. (IOVA) (Immunotherapies based on tumor infiltrating lymphocytes)

Jounce Therapeutics, Inc. (JNCE) (IPO January 27, 2017; cancer immunotherapies)

Loxo Oncology, Inc. (LOXO) (Cancer therapies)

MacroGenics, Inc. (MGNX) (Biopharmaceutical company: monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases)

Merrimack Pharmaceuticals, Inc. (MACK) (Biopharmaceutical company: cancer)

Mersana Therapeutics, Inc. (MRSN) (IPO June 28, 2017; biopharmaceutical company: cancer)

Merus N.V. (MRUS) (IPO May 19, 2016, Netherlands: immuno-oncology company)

Momenta Pharmaceuticals, Inc. (MNTA) (Therapeutics for oncology and autoimmune indications)

NewLink Genetics Corporation (NLNK) (Biopharmaceutical company: immunotherapy products, pancreatic cancer)

NovoCure Ltd. (NVCR) (IPO in October 2015, oncology company: treatment of solid tumor cancers)

OncoMed Pharmaceuticals, Inc. (OMED) (Biopharmaceutical company: antibody therapeutics targeting cancer stem cells)

Puma Biotechnology Inc. (PBYI) (Biopharmaceutical company: products for the treatment of various forms of cancer)

Rigel Pharmaceuticals, Inc. (RIGL) (Small-molecule drugs for the treatment of immune diseases and cancers)

Spectrum Pharmaceuticals, Inc. (SPPI) (Hematology, oncology)

TG Therapeutics, Inc. (TGTX) (Biopharmaceutical company: B-cell malignancies and autoimmune diseases)

Unum Therapeutics Inc. (UMRX) (IPO March 29, 2018; biopharmaceutical company: immunotherapy products)

Xbiotech Inc. (XBIT) (IPO in April 2015, biopharmaceutical company: cancer antibodies)

Ziopharm Oncology Inc. (ZIOP)  (Biopharmaceutical company: cell-based therapies for the treatment of cancer)


Akcea Therapeutics, Inc. (AKCA) (IPO July 14, 2017; biopharmaceutical company: cardiometabolic lipid disorders)

Central Nervous System

Intra-Cellular Therapies Inc. (ITCI) (Biopharmaceutical company: drugs for the treatment of diseases and disorders of the Central Nervous System)

Omeros Corporation (OMER) (Biopharmaceutical company: small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system)


Retrophin, Inc. (RTRX) (Biopharmaceutical company: catastrophic diseases affecting children)


Axovant Sciences Ltd. (AXON) (Therapeutics designed to treat dementia)


Lexicon Pharmaceuticals, Inc. (LXRX) (Biopharmaceutical company: treatment of type 1 and type 2 diabetes, treatment of carcinoid syndrome)


Otonomy, Inc. (OTIC) (Biopharmaceutical company: therapeutics for the treatment of diseases and disorders of the ear)


Kala Pharmaceuticals, Inc. (KALA) (IPO July 20, 2017; biopharmaceutical company: eye diseases)

Nightstar Therapeutics plc (NITE) (IPO September 28, 2017; gene therapy company: rare inherited retinal diseases)

Endocrine Disorders

Versartis, Inc. (VSAR) (Biopharmaceutical company: treatment of endocrine disorders)


Ardelyx, Inc. (ARDX) (Molecule therapeutics: gastrointestinal)

Seres Therapeutics Inc. (MCRB) (IPO in June 2015: microbiome therapeutics platform)

Synergy Pharmaceuticals, Inc. (SGYP) (Biopharmaceutical company: therapies for the treatment of gastrointestinal diseases and disorders)

Zealand Pharma A/S (ZEAL) (IPO August 9, 2017; biotechnology company: gastrointestinal and metabolic diseases)

Gene Control

Syros Pharmaceuticals, Inc. (SYRS) (IPO June 30, 2016: Biopharmaceutical company, gene control medicines)

Gene Editing

CRISPR Therapeutics (CRSP) (IPO October 19, 2016: Switzerland, gene editing)

Intellia Therapeutics, Inc. (NTLA) (IPO May 6, 2016: gene editing company)

Gene Therapies

Regenxbio Inc. (RGNX) (IPO in September 2015: In vivo gene therapy products designed to treat various diseases)

Spark Therapeutics, Inc. (ONCE) (Gene therapies: treatments for debilitating genetic diseases)

Voyager Therapeutics, Inc. (VYGR) (IPO in November 2015: clinical stage gene therapy company: central nervous system)


ANI Pharmaceuticals, Inc. (ANIP) (Branded and generic prescription pharmaceuticals)

Growth Hormone Deficiency

Ascendis Pharma (ASND) (IPO in January 2015: Denmark, biopharmaceutical company: growth hormone deficiency, pulmonary arterial hypertension)

Amarin Corporation Plc. (AMRN) (Ireland, biopharmaceutical company: cardiovascular health)

MyoKardia Inc. (MYOK) (IPO in October 2015: Biopharmaceutical company; therapies for serious and neglected rare cardiovascular diseases)

Immune System

Ra Pharmaceuticals, Inc. (RARX) (Complement-mediated diseases)


Agenus Inc. (AGEN) (Immunology: cancer, infectious diseases)

Infectious Diseases

BioCryst Pharmaceuticals, Inc. (BCRX) (Infectious and inflammatory diseases)

Novavax, Inc. (NVAX) (Vaccine company; products to prevent infectious diseases)

Paratek Pharmaceuticals, Inc. (PRTK) (Antibiotics)

Sinovac Biotech, Ltd. (SVA) (China: Biopharmaceutical company: vaccines that protect against human infectious diseases)


AnaptysBio, Inc. (ANAB) (IPO January 26, 2017; biotech company; inflammation)


Akebia Therapeutics, Inc. (AKBA) (Biopharmaceutical company: anemia secondary to chronic kidney disease)

Aurinia Pharmaceuticals Inc. (AUPH) (Canada, biopharmaceutical company: lupus nephritis)

Keryx Biopharmaceuticals, Inc. (KERX) (Biopharmaceutical company: renal disease)

Rockwell Medical, Inc. (RMTI) (Biopharmaceutical company: end-stage renal disease and chronic kidney disease)


Assembly Biosciences, Inc. (ASMB) (Biopharmaceutical company: treatments for hepatitis B virus infection and C. difficile-associated diarrhea)

Enanta Pharmaceuticals, Inc. (ENTA) (Small molecule drugs for viral infections and liver diseases)


Forward Pharma (FWP) (Denmark: immunomodulatory compound dimethyl fumarate and derivatives used to treat immune disorders including multiple sclerosis and psoriasis)


Cytokinetics, Incorporated (CYTK) (Biopharmaceutical company: debilitating diseases in which muscle performance is compromised and/or declining)


Acorda Therapeutics, Inc. (ACOR) (Biopharmaceutical company: neurological disorders)

Avexis Inc. (AVXS) (IPO February 11, 2016: Gene therapy company with a focus on rare neurological genetic diseases)

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) (IPO May 4, 2017; biopharmaceutical company: neurological diseases)

Vanda Pharmaceuticals Inc. (VNDA) (Biopharmaceutical company: atopic dermatitis, Non-24-Hour Disorder, schizophrenia)


Radius Health, Inc. (RDUS) (Biopharmaceutical company: osteoporosis, endocrine-mediated diseases)


Alder BioPharmaceuticals, Inc. (ALDR) (Biopharmaceutical company: migraine, autoimmune diseases and inflammatory diseases)

Cara Therapeutics, Inc. (CARA) (Chemical entities designed to alleviate pain and pruritus)

Rare Diseases

Acceleron Pharma Inc. (XLRN) (Cancer and orphan diseases)

Amicus Therapeutics, Inc. (FOLD) (Biopharmaceutical company: lysosomal storage diseases)

Audentes Therapeutics, Inc. (BOLD) (IPO July 20, 2016: biotech company focused on therapy treatments for rare diseases)

Corbus Pharmaceuticals Holdings, Inc. (CRBP) (Biopharmaceutical company: rare, life-threatening, inflammatory diseases)

Idera Pharmaceuticals, Inc. (IDRA) (B-cell Lymphoma, autoimmune, rare)

Sarepta Therapeutics, Inc. (SRPT) (Biopharmaceutical company: RNA-based therapeutics; rare and infectious diseases)

Regenerative Medicine

BioTime, Inc. (BTX) (Regenerative medicine to patients with serious diseases and degenerative conditions)

Mesoblast Ltd. (MESO) (IPO in November 2015, Australia: regenerative medicine company; areas of focus include inflammation, cardiovascular disease and back pain)


Innoviva, Inc. (INVA) (Royalty: bio-pharmaceuticals, respiratory assets)

Insmed, Inc. (INSM) (Biopharmaceutical company: lung disease and pulmonary arterial hypertension)


Dermira, Inc. (DERM) (Biopharmaceutical company: products for dermatologists and their patients)

Weight Management

Arena Pharmaceuticals, Inc. (ARNA) (Biopharmaceutical company: drugs that target G protein-coupled receptors; weight management)

Women’s Health

Myovant Sciences Ltd. (MYOV) (IPO October 27, 2016: biopharmaceutical company, women’s health and other endocrine-related disorders)